At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Pasi A. Jänne, MD, PhD, from Dana-Farber Cancer Institute, Boston, MA, discusses the results to date of LUX-Lung 7, a global, randomised, open-label, phase 2b clinical trial comparing afatinib, an irreversible ErbB family blocker, to gefitinib for the first-line treatment of patients who have epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
LUX-Lung 7: Phase 2b trial of afatinib versus gefitinib for EGFR-mutated lung cancer in first-line
4th February 2016
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.Join Now